Larotrectinib, a selective tropomyosin receptor kinase inhibitor for adult and pediatric tropomyosin receptor kinase fusion cancers.

Farago, Anna F

Larotrectinib, a selective tropomyosin receptor kinase inhibitor for adult and pediatric tropomyosin receptor kinase fusion cancers. [electronic resource] - Future oncology (London, England) Mar 2020 - 417-425 p. digital

Publication Type: Journal Article

1744-8301

10.2217/fon-2019-0647 doi


Adult
Biomarkers, Tumor--genetics
Child
Drug Resistance, Neoplasm--genetics
Humans
Membrane Glycoproteins--antagonists & inhibitors
Molecular Targeted Therapy
Neoplasms--drug therapy
Oncogene Proteins, Fusion--genetics
Protein Kinase Inhibitors--therapeutic use
Pyrazoles--therapeutic use
Pyrimidines--therapeutic use
Receptor, trkA--antagonists & inhibitors
Receptor, trkB--antagonists & inhibitors
Receptor, trkC--antagonists & inhibitors
Treatment Outcome